| Autor: |
Tenembaum SN; Hospital de Pediatría S.A.M.I.C. Prof Juan P Garrahan, Buenos Aires, Argentina. silviatenembaum@gmail.com, Banwell B, Pohl D, Krupp LB, Boyko A, Meinel M, Lehr L, Rocak S, Cantogno EV, Moraga MS, Ghezzi A |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of child neurology [J Child Neurol] 2013 Jul; Vol. 28 (7), pp. 849-56. Date of Electronic Publication: 2013 May 10. |
| DOI: |
10.1177/0883073813488828 |
| Abstrakt: |
To expand current knowledge, we examined the safety and tolerability of subcutaneous interferon β-1a in patients with pediatric-onset multiple sclerosis. Records from 307 patients who had received at least 1 injection of subcutaneous interferon β-1a for demyelinating events when aged younger than 18 years were reviewed. Overall, 168 (54.7%) patients had at least 1 prespecified medical event related to or under close monitoring with subcutaneous interferon β-1a or specific to pediatric patients, 184 (59.9%) had nonserious medical events related to treatment or of unknown causality, and 12 (3.9%) had serious medical events irrespective of causality. The most common laboratory abnormalities were increased alanine (74/195; 37.9%) and aspartate aminotransferase levels (59/194; 30.4%). Annualized relapse rates were 1.79 before treatment and 0.47 during treatment. In conclusion, adult doses of subcutaneous interferon β-1a (44 and 22 μg, 3 times weekly) were well tolerated in pediatric patients and were associated with reduced relapse rates. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
